To assess the predicted repression of NFE2L2-dependent transcriptional networks, OE19 esophageal adenocarcinoma cells were treated with halcinonide, methylprednisolone, or rosiglitazone (1 μM, 24 h) followed by RNA-seq profiling (n = 2 per condition). The gene discussed is NFE2L2; the disease is esophageal adenocarcinoma.